-
公开(公告)号：US10899814B2
公开(公告)日：2021-01-26
申请号：US16917230
申请日：2020-06-30
发明人： Heiko Schuster , Annika Sonntag , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh , Colette Song
IPC分类号： A61K35/17 , C07K14/47 , C07K14/725 , C07K14/74 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10435454B2
公开(公告)日：2019-10-08
申请号：US16165121
申请日：2018-10-19
发明人： Annika Sonntag , Toni Weinschenk , Andrea Mahr , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , G16B25/00 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/28 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , A61K38/04 , A61P37/04 , A61P35/00 , A61K38/17 , C07K7/06
摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
-
公开(公告)号：US12060399B2
公开(公告)日：2024-08-13
申请号：US17471754
申请日：2021-09-10
发明人： Heiko Schuster , Annika Sonntag , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh , Colette Song
IPC分类号： C07K14/00 , C07K14/47 , C07K14/725 , C07K14/74 , A61K38/00
CPC分类号： C07K14/4748 , C07K14/7051 , C07K14/70539 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10364281B2
公开(公告)日：2019-07-30
申请号：US16167656
申请日：2018-10-23
发明人： Annika Sonntag , Toni Weinschenk , Andrea Mahr , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , G16B25/00 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/28 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , A61K38/04 , A61P37/04 , A61P35/00 , A61K38/17 , C07K7/06
摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
-
公开(公告)号：US10954281B2
公开(公告)日：2021-03-23
申请号：US16575250
申请日：2019-09-18
发明人： Heiko Schuster , Annika Sonntag , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh , Colette Song
IPC分类号： A61K38/00 , C07K14/47 , C07K14/725 , C07K14/74
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10519216B2
公开(公告)日：2019-12-31
申请号：US16503901
申请日：2019-07-05
发明人： Annika Sonntag , Toni Weinschenk , Andrea Mahr , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , A61K35/17 , A61K38/17 , A61P35/00 , A61P37/04 , A61K38/04 , C07K7/06 , G01N33/574 , C12N5/0783 , C12Q1/6886 , C12N15/115 , C07K16/28 , C07K14/725 , A61K39/00 , G16B25/00
摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
-
公开(公告)号：US20190322722A1
公开(公告)日：2019-10-24
申请号：US16503901
申请日：2019-07-05
发明人： Annika Sonntag , Toni Weinschenk , Andrea Mahr , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , G16B25/00 , A61K35/17 , A61K38/17 , A61P35/00 , A61P37/04 , A61K38/04 , C07K7/06 , G01N33/574 , C12N5/0783 , C12Q1/6886 , C12N15/115 , C07K16/28 , C07K14/725 , A61K39/00
摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
-
公开(公告)号：US10385111B2
公开(公告)日：2019-08-20
申请号：US16165275
申请日：2018-10-19
发明人： Annika Sonntag , Toni Weinschenk , Andrea Mahr , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , G16B25/00 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/28 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , A61K38/04 , A61P37/04 , A61P35/00 , A61K38/17 , C07K7/06
摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
-
公开(公告)号：US20190040114A1
公开(公告)日：2019-02-07
申请号：US16165275
申请日：2018-10-19
发明人： Annika Sonntag , Toni Weinschenk , Andrea Mahr , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC分类号： C07K14/74 , C07K16/28 , G01N33/574 , A61K39/00 , C12N5/0783 , C07K14/725 , G06F19/20 , A61K38/17 , C12Q1/6886 , A61K35/17 , C12N15/115
CPC分类号： C07K14/70539 , A61K35/17 , A61K38/04 , A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61P35/00 , A61P37/04 , C07K7/06 , C07K14/7051 , C07K16/2833 , C12N5/0636 , C12N5/0638 , C12N15/115 , C12N2310/16 , C12N2502/11 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/574 , G01N33/57484 , G01N2333/70539 , G16B25/00
摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
-
10.发明授权公开(公告)号：US11779605B2
公开(公告)日：2023-10-10
申请号：US16717142
申请日：2019-12-17
发明人： Gisela Schimmack , Annika Sonntag , Heiko Schuster , Daniel Johannes Kowalewski , Michael Roemer , Jens Fritsche , Oliver Schoor , Toni Weinschenk , Harpreet Singh
CPC分类号： A61K35/17 , A61K39/0011 , C07K14/70514 , C07K14/70517 , C07K14/70539 , C07K16/00 , A61K2039/605
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.024 秒)
